A Phase I/II proof-of-concept study evaluating CP-383
Latest Information Update: 16 Dec 2024
Price :
$35 *
At a glance
- Drugs CP 383 (Primary)
- Indications Cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- 16 Dec 2024 New trial record